No Data
*ST Jingfeng (000908.SZ): The main business currently has no other significant changes. Trading will resume on November 21.
On November 20, Gelonghui reported that *ST Jingfeng (000908.SZ) announced that according to the relevant regulations including the "Guidelines for Self-Discipline Supervision for Listed Companies No. 6 - Suspension and Resumption of Trading" issued by the Shenzhen Stock Exchange, upon the company's application, the company's stocks (abbreviated as *ST Jingfeng, stock code: 000908) will resume trading starting on November 21, 2024 (Thursday). The company's stock price has increased by 752.78% from July 3, 2024, to November 15, 2024, with significant price fluctuations. The company reminds all investors to pay attention to the trading risks in the secondary market. After consulting with the company management and controlling shareholder.
*Special treat Jingfeng (000908.SZ): Suspended for verification from the market opening on November 18th.
On November 17, 2023, *ST Jingfeng (000908.SZ) announced that the price increase of its stocks from July 3, 2024, to November 15, 2024, was 752.78%. The stock price has been quite volatile, drawing considerable attention from investors. To protect the interests of investors, the company will investigate the fluctuations in stock trading. Upon the company's application, trading of the stocks will be suspended starting November 18, 2024, until the investigation concludes and the relevant announcement is disclosed, with the suspension expected to last no more than three trading days. Verification has been conducted with the company's management, controlling shareholders, and actual controllers.
*Special Treat Jingfeng (000908.SZ): The holding subsidiary is planning to authorize and act as an agent for pharmaceutical products with related parties.
gelonhui on November 11th: *ST Jingfeng (000908.SZ) announced that its holding subsidiary Shanghai Jingfeng Pharmaceutical Co., Ltd. is planning to engage in daily related party transactions of authorized agent pharmaceutical products with its affiliate Hebei Zhongcheng Pharmaceutical Co., Ltd. (referred to as "Zhongcheng Pharmaceutical") for development needs. The amount of the related party transaction is expected to be no more than 30 million RMB, and the above limit is valid for one year from the date of approval by the shareholders' meeting. The main content of this daily related party transaction is for Shanghai Jingfeng to sell sodium glycoxylate injection to Zhongcheng Pharmaceutical and authorize Zhongcheng Pharmaceutical for exclusive sales promotion and distribution nationwide.
*ST Jingfeng: Report for the third quarter of 2024
*ST Jingfeng (000908.SZ): Intends to carry out commissioned research and development.
Gelonghui, October 18th | *ST Jingfeng (000908.SZ) announced that, according to the development needs, the company and its holding subsidiaries plan to engage in related-party entrusted research and development with the subsidiary of the related party CSPC Pharma Holdings Co., Ltd. (referred to as "CSPC Pharma Group"), named CSPC Pharma Group Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (referred to as "CSPC Zhongqi"), with a total expected transaction amount not exceeding 10 million yuan. The above limit is valid for three years from the date of approval by the board of directors.
ST Jingfeng (000908.SZ) subsidiary Shanghai Jingfeng plans to sell its property located in Suzhou city at a price of 64.6928 million yuan.
*ST Jingfeng (000908.SZ) announced that its wholly-owned subsidiary shanghai Jingfeng Pharmaceutical Co., Ltd. (referred to as "shanghai...
Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five Years
